Medicines Development for Global Health
12
1
2
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
8.3%
1 terminated/withdrawn out of 12 trials
87.5%
+1.0% vs industry average
42%
5 trials in Phase 3/4
57%
4 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
Role: lead
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
Role: lead
Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction
Role: lead
Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
Role: collaborator
Better Options for Lymphatic Filariasis Treatment
Role: lead
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
Role: lead
Efficacy and Safety Study of Moxidectin in Adults With Scabies
Role: lead
Dose-finding Study of Moxidectin for Treatment of Scabies
Role: lead
Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection
Role: lead
Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers
Role: lead
A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People
Role: lead
Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
Role: lead
All 12 trials loaded